Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Globe Newswire•22/10/2026•08:00 ET
0
Key Highlights
- ➤CRB-913 Canyon-1 Phase 1B data will be presented at Obesity Week 2026
- ➤Poster presentation scheduled November 15, 2026, from 2:30–3:30 p.m. ET
- ➤Harold Bays, M.D. will present CRB-913 efficacy, safety, and tolerability data
- ➤CRB-913 is an oral, peripherally restricted CB1 inverse agonist for obesity
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be presented as a poster presentation at Obesity Week(®) 2026, taking place from November 14–17, 2026 in National Harbor, MD.
Title: Efficacy, Safety, and Tolerability of CRB-913 in the Ph1b CANYON-1 Study Presenter: Harold Bays, M.D, Louisville Metabolic and Atherosclerosis Research Center Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET Location: Gaylord National Resort & Convention Center: Exhibit Hall BCD
Get started
Create a free account to read the full story.